Aloxi® injection is the first and only 5-HT3 receptor antagonist to be indicated for the prevention of both acute and delayed CINV caused by moderately-emetogenic chemotherapy. Click here for prescribing information MGI PHARMA markets Salagen® Tablets as a treatment for the symptoms of dry mouth associated with radiation therapy for head and neck cancer and Sjögren's syndrome. Click here for prescribing information Hexalen® capsules are an orally administered chemotherapeutic agent for the treatment of refractory ovarian cancer. Click here for prescribing information 07/29/05: MGI PHARMA at Banc of America Securities Specialty Pharmaceuticals Conference 07/21/05: MGI PHARMA to Acquire Guilford Pharmaceuticals >> Webcast Link 07/22/05: MGI PHARMA To Present at the Banc of America Securities 2005 Specialty Pharmaceuticals Conference 07/21/05: MGI PHARMA to Acquire Guilford Pharmaceuticals 07/13/05: MGI PHARMA Reports Second Quarter Results 07/06/05: MGI PHARMA Second Quarter 2005 Financial Results Conference Call to Be Webcast on July 13, 2005